TwinStrand Biosciences™, a spin-out of the University of Washington, is a novel genetic sequencing technology company leading the way in identifying rare genetic variants undetectable by current sequencing methods.

TwinStrand Biosciences develops and commercializes the Duplex Sequencing™ technology for DNA sequencing.

TwinStrand Biosciences was founded in 2015 and is headquartered in Seattle, Washington.

TwinStrand's TwinStrand's highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health, and other fields of science on a faster timescale, where actions are most impactful.

TwinStrand's scientist-leaders have authored more than two dozen peer-reviewed articles using Duplex Sequencing Technology and have developed a portfolio of more than 100 patents and patent applications.

TwinStrand has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science.

TwinStrand is backed by Madrona Venture Group, Section 32, Alexandria Venture Investments, Soleus Capital, Janus Henderson Investors, Ridgeback Capital, Sahsen Ventures and others. The company raised $50M in Series B round on May 06, 2021. This brings TwinStrand's total funding to $77.9M to date.